trastuzumab Ligand page

trastuzumab Ligand page trastuzumab Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW: KD trastuzumab A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in

trastuzumab Trastuzumab was developed by Genentech Inc as a recombinant humanized monoclonal antibody directed against the

trastuzumab Trastuzumab works by binding to HER2, a protein involved in cell growth found in large amounts on some cancer cells This binding blocks the Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and